| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 9.96▲ | 9.97▲ | 9.96▲ | 9.97▲ | 9.94▲ |
| MA10 | 9.96▲ | 9.95▲ | 9.95▲ | 9.97▲ | 9.92▲ |
| MA20 | 9.95▲ | 9.95▲ | 9.96▲ | 9.95▲ | 9.86▲ |
| MA50 | 9.96▲ | 9.96▲ | 9.96▲ | 9.91▲ | 9.71▲ |
| MA100 | 9.96▲ | 9.95▲ | 9.94▲ | 9.85▲ | 9.66▲ |
| MA200 | 9.94▲ | 9.93▲ | 9.91▲ | 9.68▲ | 9.51▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.002▲ | 0.005▲ | 0.003▲ | -0.001▼ | 0.008▲ |
| RSI | 58.280▲ | 59.775▲ | 56.327▲ | 57.570▲ | 60.681▲ |
| STOCH | 78.889 | 85.370▲ | 67.778 | 71.708 | 75.910 |
| WILL %R | 0.000▲ | 0.000▲ | -7.692▲ | -12.500▲ | -8.621▲ |
| CCI | 76.988 | 49.664 | 35.897 | 34.221 | 87.085 |
|
Tuesday, September 30, 2025 05:56 AM
Watch the "What This Means" video here Featuring Company’s second-generation T-Cell Engager program and advantages over first-generation Company’s T-Cell Engager program has made improvements in ...
|
|
Monday, September 29, 2025 07:15 AM
Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, today announced that it has appointed Andrew (Andy) Bayliffe, PhD, as Chief Development Officer. Andy ...
|
|
Monday, September 29, 2025 04:30 AM
(Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Christophe ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 01/10/25 | 9.93 | 9.975 | 9.93 | 9.975 | 65,164 |
| 30/09/25 | 9.94 | 9.98 | 9.91 | 9.96 | 184,356 |
| 29/09/25 | 9.96 | 9.965 | 9.92 | 9.95 | 193,318 |
| 26/09/25 | 9.95 | 9.98 | 9.95 | 9.96 | 107,700 |
| 25/09/25 | 9.97 | 9.99 | 9.97 | 9.98 | 175,800 |
| 24/09/25 | 9.97 | 9.99 | 9.96 | 9.98 | 146,200 |
| 23/09/25 | 9.98 | 9.99 | 9.96 | 9.99 | 177,200 |
| 22/09/25 | 9.95 | 9.97 | 9.95 | 9.97 | 121,300 |
| 19/09/25 | 9.95 | 9.97 | 9.95 | 9.96 | 134,100 |
| 18/09/25 | 9.95 | 9.96 | 9.94 | 9.95 | 198,200 |
|
|
||||
|
|
||||
|
|